Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EF-022 in Adult RRP
NCT02854761Phase 1Unknown
- Sponsor
- Efranat Ltd.
- Start
- Sep 2016
- Primary completion
- Sep 2018
- Modality
- Cytokines & Interferons
01
Overview
Phase 1, open-label trial of gcmaf in recurrent respiratory papillomatosis (RRP) (2 arms), sponsored by Efranat Ltd. Primary endpoint: Adverse Events according to CTCAE v.4.03 criteria at 6 months. Status: unknown.
02
Drugs
gcmaf
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT02854761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02854761.